310 related articles for article (PubMed ID: 31203241)
1. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
[TBL] [Abstract][Full Text] [Related]
2. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T
BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242
[TBL] [Abstract][Full Text] [Related]
3. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489
[TBL] [Abstract][Full Text] [Related]
5. Effects of Molidustat in the Treatment of Anemia in CKD.
Macdougall IC; Akizawa T; Berns JS; Bernhardt T; Krueger T
Clin J Am Soc Nephrol; 2019 Jan; 14(1):28-39. PubMed ID: 30559105
[TBL] [Abstract][Full Text] [Related]
6. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T
Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574
[TBL] [Abstract][Full Text] [Related]
8. Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study.
Akizawa T; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Yamamoto H
Ther Apher Dial; 2021 Dec; 25(6):917-925. PubMed ID: 33506635
[TBL] [Abstract][Full Text] [Related]
9. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials.
Yamamoto H; Yamada T; Miyazaki K; Yamashita T; Kato T; Ohara K; Nakamura Y; Akizawa T
Clin Exp Nephrol; 2023 Aug; 27(8):651-659. PubMed ID: 37095342
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
[TBL] [Abstract][Full Text] [Related]
11. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
Eckardt KU; Agarwal R; Farag YM; Jardine AG; Khawaja Z; Koury MJ; Luo W; Matsushita K; McCullough PA; Parfrey P; Ross G; Sarnak MJ; Vargo D; Winkelmayer WC; Chertow GM
Nephrol Dial Transplant; 2021 Nov; 36(11):2039-2048. PubMed ID: 33188693
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
[TBL] [Abstract][Full Text] [Related]
13. Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis.
Akizawa T; Yamada T; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Yamamoto H
Kidney Int Rep; 2021 Oct; 6(10):2604-2616. PubMed ID: 34622100
[TBL] [Abstract][Full Text] [Related]
14. Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
Akizawa T; Nobori K; Matsuda Y; Taki K; Hayashi Y; Hayasaki T; Yamamoto H
Ther Apher Dial; 2022 Apr; 26(2):368-377. PubMed ID: 34310049
[TBL] [Abstract][Full Text] [Related]
15. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
[TBL] [Abstract][Full Text] [Related]
16. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
17. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
18. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
Hahn D; Cody JD; Hodson EM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
[TBL] [Abstract][Full Text] [Related]
20. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
